Maintenance immunosuppression in renal transplantation

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 662-671

  Menon, Madhav C ^a   Murphy, Barbara ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ANTICONVULSIVE AGENT; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BOCEPREVIR; BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; GLUCOCORTICOID; GRAPEFRUIT EXTRACT; IMMUNOGLOBULIN; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METRONIDAZOLE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; RAPAMYCIN; RIFAMYCIN; RITUXIMAB; TACROLIMUS; TELAPREVIR; UNINDEXED DRUG;

ABDOMINAL PAIN; ACIDOSIS; ACNE; ACUTE GRAFT REJECTION; ANEMIA; ANTIGEN PRESENTING CELL; ARTHRALGIA; ARTICLE; BK VIRUS INFECTION; BONE MARROW SUPPRESSION; CANDIDIASIS; CD4+ T LYMPHOCYTE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FEVER; FOCAL GLOMERULOSCLEROSIS; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; GRAPEFRUIT JUICE; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HERPES SIMPLEX; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LYMPHOCELE; MAINTENANCE THERAPY; NEOPLASM; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PEPTIC ULCER; PNEUMOCYSTIS PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEINURIA; PURE RED CELL ANEMIA; QT PROLONGATION; RASH; RHEUMATOID ARTHRITIS; SECONDARY INFECTION; SEROMA; SIDE EFFECT; SKIN CANCER; STOMATITIS; TERATOGENICITY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; TUBERCULOSIS; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

EID: 84885960929     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.004     Document Type: Review

References (115)

1. Afzali B, Lombardi G, Lechler RI: Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008, 13:438-444.
2. Hornick P: Direct and indirect allorecognition. Methods Mol Biol 2006, 333:145-156.
3. Jenkins MK, Taylor PS, Norton SD, Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991, 147:2461-2466.
4. Noel PJ, Boise LH, Thompson CB: Regulation of T cell activation by CD28 and CTLA4. Adv Exp Med Biol 1996, 406:209-217. (Pubitemid 26357357)
5. Rudd CE: CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets. Eur J Immunol 2009, 39:687-690.
6. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351:2715-2729. (Pubitemid 39665325)
7. Johnston JA, Kawamura M, Kirken RA, Chen YQ, Blake TB, Shibuya K, Ortaldo JR, McVicar DW, O'Shea JJ: Phosphorylationand activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994, 370:151-153. (Pubitemid 24229128)
8. Gomez-Valades AG, Llamas M, Blanch S, Perales JC, Roman J, Gomez-Casajus L, Mascaro C: Specific Jak3 downregulation in lymphocytes impairs gammac cytokine signal transduction and alleviates antigen-driven inflammation in vivo. Mol Ther Nucleic Acids 2012, 1:e42.
9. Moran E, Carbone F, Augusti V, Patrone F, Ballestrero A, Nencioni A: Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol 2012, 49:270-276.
10. Borel JF, Feurer C, Gubler HU, Stahelin H: Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976, 6:468-475.
11. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K: Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978, 2:1323-1327. (Pubitemid 9078430)
12. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Henderson RG, Aziz S et al.: Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979, 2:1033-1036. (Pubitemid 10213970)
13. Starzl TE, Klintmalm GB, Weil R III, Porter KA, Iwatsuki S, Schroter GP, Fernandez-Bueno C, MacHugh N: Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1981, 153:486-494. (Pubitemid 11007294)
14. Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Preliminary results of a European multicentre trial. Lancet 1982, 2:57-60.
15. Canadian: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983, 309:809-815.
16. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med 1986, 314:1219-1225.
17. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987, 40:1256-1265. (Pubitemid 17138110)
18. Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M et al.: Kidney transplantation under FK 506. JAMA 1990, 264:63-67. (Pubitemid 20209172)
19. Busque S, Shoker A, Landsberg D, McAlister V, Halloran P, Shapiro J, Peets J, Schulz M: Canadian multicentre trial of tacrolimus/azathioprine/ steroids versus tacrolimus/ mycophenolate mofetil/steroids versus neoral/ mycophenolate mofetil/steroids in renal transplantation. Transplant Proc 2001, 33:1266-1267. (Pubitemid 32237839)
20. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C III, Rocher L, Scandling J et al.: Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000, 69:834-841. (Pubitemid 30174107)
21. Margreiter R, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study G: Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002, 359:741-746. (Pubitemid 34215073)
22. Morris-Stiff G, Ostrowski K, Balaji V, Moore R, Darby C, Lord R, Jurewicz WA: Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Transpl Int 1998, 11(Suppl 1):S334-S336. (Pubitemid 128683573)
23. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC: Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: metaanalysis and meta-regression of randomised trial data. BMJ 2005, 331:810.
24. Casey MJ, Meier-Kriesche HU: Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens 2011, 20:610-615.
25. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U et al.: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575. (Pubitemid 350294223)
26. Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC et al.: Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007, 83:883-892. (Pubitemid 46682728)
27. Flechner SM, Glyda M, Cockfield S, Grinyo J, Legendre C, Russ G, Steinberg S, Wissing KM, Tai SS: The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011, 11:1633-1644.
28. Moore J, Middleton L, Cockwell P, Adu D, Ball S, Little MA, Ready A, Wheatley K, Borrows R: Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009, 87:591-605.
29. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G et al.: A phase III study of belataceptbased immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
30. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R: Metaanalysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011, 22:2107-2118.
31. Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F, Vanrenterghem Y, Kramer BK, Abramowicz D, Oppenheimer F et al.: Pharmacokinetics for once- versus twicedaily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009, 9:2505-2513.
32. Kramer BK, Charpentier B, Backman L, Silva HT Jr, Mondragon- Ramirez G, Cassuto-Viguier E, Mourad G, Sola R, Rigotti P, Mirete JO et al.: Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010, 10:2632-2643.
33. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE: Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs 2011, 71:1561-1577.
34. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y: Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010, 90:523-529.
35. Wang YY, Zhang M, Lu FM, Jiao Z, Qiu XY: CYP3A4 genetic polymorphisms predict cyclosporine-related clinical events inChinese renal transplant recipients. Chin Med J (Engl) 2012, 125:4233-4238.
36. Elens L, Van Gelder T, Hesselink DA, Haufroid V, van Schaik RH: CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013, 14:47-62
37. Wang YY, Zhang M, Lu FM, Jiao Z, Qiu XY: CYP3A4 genetic polymorphisms predict cyclosporine-related clinical events inChinese renal transplant recipients. Chin Med J (Engl) 2012, 125:4233-4238.
38. Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE: CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation 2013.
39. Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN: Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant 2012, 17:111-121.
40. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine- associated chronic nephropathy. N Engl J Med 1984, 311:699-705. (Pubitemid 14074555)
41. Gaston RS: Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009, 4:2029-2034.
42. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M et al.: Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514. (Pubitemid 46776239)
43. Shi Y, Moriyama T, Namba Y, Yamanaka M, Hanafuse T, Imamura R, Ichimaru N, Oka K, Kyo M, Tian Y et al.: Association of treatment with 15-deoxyspergualin and BK virus nephropathy in kidney allograft recipients. Clin Transplant 2007, 21:502-509. (Pubitemid 47161827)
44. Koukoulaki M, Grispou E, Pistolas D, Balaska K, Apostolou T, Anagnostopoulou M, Tseleni-Kotsovili A, Hadjiconstantinou V, Paniara O, Saroglou G et al.: Prospective monitoring of BK virus replication in renal transplant recipients. Transpl Infect Dis 2009, 11:1-10.
45. Acott P, Babel N: BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? Ann Transplant 2012, 17:86-99.
46. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995, 345:1321-1325.
47. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996, 61:1029-1037.
48. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60:225-232.
49. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C: Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997, 63:39-47. (Pubitemid 27036687)
50. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000, 69:2405-2409. (Pubitemid 30409012)
51. Meier-Kriesche HU, Ojo AO, Leichtman AB, Punch JD, Hanson JA, Cibrik DM, Kaplan B: Effect of mycophenolate mofetil on longterm outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000, 11:2366-2370.
52. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M, Groups EBS: Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004, 4:231-236. (Pubitemid 38248526)
53. Lipsky JJ: Mycophenolate mofetil. Lancet 1996, 348:1357-1359. (Pubitemid 26383778)
54. Bjarnason I: Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 2001, 33:3238-3240. (Pubitemid 34042556)
55. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M, Group EBS: Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004, 4:237-243. (Pubitemid 38248527)
56. Chan L, Mulgaonkar S, Walker R, Arns W, Ambuhl P, Schiavelli R: Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006, 81:1290-1297. (Pubitemid 43804549)
57. Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, Dakshinamurthy KV, Vijaykumar R, Abraham G, Bhaskar S et al.: Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008, 40:2262-2267.
58. Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L, Cooper M, Langone AJ, Tomlanovich SJ: Improvement in 3- month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007, 84:1443-1451. (Pubitemid 350294719)
59. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT: Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006, 82:1698-1702. (Pubitemid 46035654)
60. Sehgal SN, Baker H, Vezina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975, 28:727-732.
61. Martel RR, Klicius J, Galet S: Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977, 55:48-51. (Pubitemid 8061941)
62. Eng CP, Sehgal SN, Vezina C: Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984, 37:1231-1237. (Pubitemid 14015835)
63. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000, 356:194-202. (Pubitemid 30446974)
64. MacDonald AS, Group RGS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271-280.
65. Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH: SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997, 64:36-42. (Pubitemid 27327197)
66. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N et al.: Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005, 80:244-252. (Pubitemid 41061682)
67. Vitko S, Klinger M, Salmela K, Wlodarczyk Z, Tyden G, Senatorski G, Ostrowski M, Fauchald P, Kokot F, Stefoni S et al.: Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/ mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005, 80:1734-1741. (Pubitemid 43053999)
68. Kahan BD: Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997, 29:48-50. (Pubitemid 27123317)
69. Wang ME, Stepkowski SM, Ferraresso M, Kahan BD: Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Transplantation 1992, 54:704-709.
70. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002, 74:1070-1076. (Pubitemid 35216097)
71. Gelens MA, Christiaans MH, van Heurn EL, van den Berg- Loonen EP, Peutz-Kootstra CJ, van Hooff JP: High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation 2006, 82:1221-1223. (Pubitemid 44748026)
72. van den Akker JM, Hene RJ, Hoitsma AJ: Inferior results with basis immunosuppression with sirolimus in kidney transplantation. Neth J Med 2007, 65:23-28. (Pubitemid 46152291)
73. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D et al.: Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009, 9:1115-1123.
74. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R et al.: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242.
75. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F et al.: Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377:837-847.
76. Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wuthrich RP, Scheidl S, May C, Paulus EM et al.: Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3- year results from the randomized ZEUS study. Am J Transplant 2012, 12:1528-1540.
77. Inza A, Balda S, Alvarez E, Zarraga S, Gainza FJ, Lampreabe I: Conversion to everolimus in kidney transplant recipients with decreased renal function. Transplant Proc 2009, 41:2134-2136.
78. Boratynska M, Banasik M, Watorek E, Falkiewicz K, Patrzalek D, Szyber P, Klinger M: Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006, 38:101-104.
79. Alarrayed SM, El-Agroudy AE, Alarrayed AS, Al Ghareeb SM, Garadah TS, El-Sharqawi SY, Al-Aradi AH, Dandi BG, Abdulla S: Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience. Clin Exp Nephrol 2010, 14:248-255.
80. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Peraldi MN, Helal I, Noel LH, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007, 2:326-333.
81. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A et al.: Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012, 367:329-339.
82. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227. (Pubitemid 24291979)
83. Webb LM, Walmsley MJ, Feldmann M: Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996, 26:2320-2328. (Pubitemid 26340930)
84. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993, 178:1801-1806. (Pubitemid 23318461)
85. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF et al.: Treatment of rheumatoid arthritis by selective inhibition of Tcell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915. (Pubitemid 37409707)
86. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, Anderson D, Cowan S, Price K, Naemura J et al.: Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5:443-453. (Pubitemid 40313335)
87. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G et al.: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010, 10:547-557.
88. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G et al.: Threeyear outcomes from BENEFIT, a randomized, activecontrolled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012, 12:210-217.
89. Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, Garcia VD, Kamar N, Lang P, Manfro RC et al.: Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012, 12:630-639.
90. van den Hoogen MW, Pipeleers L: Three-year outcomes of belatacept studies; reason to be optimistic? Am J Transplant 2012, 12:2259 discussion 2260.
91. Wekerle T, Grinyo JM: Belatacept: from rational design to clinical application. Transpl Int 2012, 25:139-150.
92. Suthanthiran M, Strom TB: Renal transplantation. N Engl J Med 1994, 331:365-376.
93. Steiner RW, Awdishu L: Steroids in kidney transplant patients. Semin Immunopathol 2011, 33:157-167.
94. Knudsen PJ, Dinarello CA, Strom TB: Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987, 139:4129-4134. (Pubitemid 18013709)
95. Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, Meco D, Petrangeli E, Frati L, Gulino A: Glucocorticoid receptormediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992, 175:637-646.
96. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB: Abrogation of glucocorticoid-mediated inhibition ofT cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991, 146:3523-3527.
97. Matas AJ: Minimization of steroids in kidney transplantation. Transpl Int 2009, 22:38-48.
98. Vincenti F: Are calcineurin inhibitors-free regimens ready for prime time? Kidney Int 2012, 82:1054-1060.
99. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A: Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003, 3:306-311 (Pubitemid 36407049)
100. ter Meulen CG, van Riemsdijk I, Hene RJ, Christiaans MH, Borm GF, van Gelder T, Hilbrands LB, Weimar W, Hoitsma AJ: Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004, 4:803-810. (Pubitemid 38637581)
101. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, Astellas Corticosteroid Withdrawal Study G: A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008, 248:564-577.
102. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J, Group FS: A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008, 8:307-316.
103. Sola E, Alferez MJ, Cabello M, Burgos D, Gonzalez Molina M: Lowdose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. Transplant Proc 2002, 34:1689-1690.
104. Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K: Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006, 82:55-61. (Pubitemid 44296978)
105. Wlodarczyk Z, Walaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, Klinger M, Szenohradszky P, Studenik P et al.: Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens. Transpl Int 2005, 18:157-162. (Pubitemid 41743305)
106. Buchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, Hurault de Ligny B, Le Meur Y, Thierry A, Villemain F et al.: Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6- month course of steroids. Am J Transplant 2007, 7:2522-2531. (Pubitemid 47561618)
107. Hricik DE, Augustine JJ, Knauss TC, Bodziak KA, Aeder M, Siegel C, Schulak JA: Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2007, 83:277-281.
108. Pascual J, Quereda C, Zamora J, Hernandez D, Spanish Group for Evidence-Based Medicine in Renal T: Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 2005, 37:3746-3748. (Pubitemid 43015153)
109. Pascual J, Quereda C, Zamora J, Hernandez D, Spanish Group for Evidence-Based Medicine in Renal T: Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004, 78:1548-1556. (Pubitemid 39552943)
110. Sinclair NR: Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992, 147:645-657.
111. Hricik DE, O'Toole MA, Schulak JA, Herson J: Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993, 4:1300-1305.
112. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000, 11:1910-1917.
113. Ferguson R, Grinyo J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, Marks WH, Agarwal M, Wu D et al.: Immunosuppression with belatacept-based, corticosteroidavoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011, 11:66-76.
114. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC, Investigators TS: A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin in living-donor kidney transplantation. Clin Transplant 2010, 24:73-83.
115. Montagnino G, Sandrini S, Iorio B, Schena FP, Carmellini M, Rigotti P, Cossu M, Altieri P, Salvadori M, Stefoni S et al.: A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008, 23:707-714. (Pubitemid 351767624)